Rehabilitation by Eccentric Exercise in Heart Failure Patients (REX-HF)

June 9, 2023 updated by: University Hospital, Clermont-Ferrand

Enhanced Effectiveness of Combined Eccentric and Concentric Exercise Over Traditional Cardiac Exercise Rehabilitation Program in Patients With Chronic Heart Failure: a Randomized Controlled Study

As part of the regular rehabilitation program for chronic heart failure (CHF) patients, the addition of dynamic eccentric endurance (ECC) exercise sessions to the conventional concentric cycling program (CON) would enable greater gains in functional capacity that the CON alone. Furthermore, in the case of severe heart failure, results of conventional exercise rehabilitation remains limited on account of the poor physical fitness and deconditioning. Dynamic ECC has been shown to enhance muscle mass and improve muscle strength in subjects with functional limitations comparable to those in CHF, but to date reports on effects on muscle endurance and overall functional capacity remain scarce or non-existent.

Investigator hypothesize that a combination of these two types of training will allow both an improvement in strength and oxidative muscle capacities. These benefits must be objectified at the level of the walking distance covered in 6 min (6-WT).

Study Overview

Detailed Description

Investigator hypothesize that the combination of CON and ECC forms of endurance exercise will potentiate peripheral muscle and cardio-circulatory adaptations. All sessions, regardless of the modality, will be performed at the same percentage of the concentric peakVO2. Sessions performed in ECC mode will induce a mechanical overload. The ECC training of such intensity and duration seemingly having little or no effect on mitochondrial muscle adaptations, the maintenance of conventional training will allow stimulation of the aerobic endurance component. A synergistic effect is expected from the combination of the two modalities; the muscle strength gain induced by ECC allowing to sustained greater cycling workloads yet compatible with the cardio-circulatory capabilities of patients with CHF and more specifically their exercise cardiac output adjustment.

Investigator chose to assess the extent of benefits through functional capacity tests reflecting adaptation of both the aerobic (endurance capacity) and anaerobic (muscle strength) components of adaptive response, namely, 1) 6 min. walk test (6-WT), 2) time up and go test (TUGT), 3) quadriceps isometric muscular strength (IMS) and gait speed test.

The study is a prospective, open, controlled and randomized study in two parallel groups carried out in a single center. Patients will be included in the study if: i) they are referred to the cardiac rehabilitation center for the 5-week training program, ii) they meet the inclusion criteria and iii) they provide their signed consent.

Patients will be followed for 5 weeks, the duration of the cardiac rehabilitation program. They will benefit from the standard evaluation of any CHF patient referred for rehabilitation including an initial 12-lead ECG, a trans-thoracic cardiac ultrasound assessment and a cycling exercise stress test with gas exchange analysis and non-invasive measurement of cardiac output using a bio-impedance device. A standard biological blood analysis will be performed for NFS-platelets, blood electrolytes, CRP, NTproBNP, nutritional status with albumin and pre-albumin.

All subjects will perform 5 exercise sessions per week on a cycle ergometer. As per randomization outcome, the "intervention" group will perform three of the five weekly sessions in ECC mode (the other two in CON) while the control group will perform the five weekly sessions in CON mode.

The intensity of the cycling will be the same in both groups as determined from the initial cycling incremental test targeted to correspond to the VO2 associated with the ventilatory threshold.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Clermont-Ferrand, France, 63003
        • CHU Clermont-Ferrand

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient with systolic chronic heart failure
  • Patients aged 18 to 75 years
  • Referred for participation in the 5-week rehabilitation program
  • At a time distance from an acute coronary syndrome or myocarditis (less than 3 months old) and clinically stabilized.
  • Beneficiary or affiliated with social security coverage

Exclusion Criteria:

  • All the usual criteria considered contra-indicated for cardiac exercise rehabilitation according to the consensus recommendations ( REF)
  • Non-stabilized acute coronary syndrome
  • Decompensated heart insufficiency
  • Stage IV NYHA
  • Severe, uncontrolled disturbances in ventricular rhythm
  • Presence of an intracardiac thrombus with high risk of embolism
  • Presence of pericardial effusion of medium to high importance
  • Recent history of thrombophlebitis with or without pulmonary embolism
  • Obstacle to severe and / or symptomatic left ventricular ejection
  • Any progressive inflammatory and / or infectious condition
  • Severe and symptomatic pulmonary arterial hypertension
  • Inability to perform physical activity
  • Reversible heart disease
  • Patients undergoing circulatory assistance
  • Patients taking blood thinner medication (except Kardegic-type aggregates and direct oral anticoagulants)
  • Patients with known allergy to Xylocaine
  • Pregnant or lactating women
  • Women of childbearing age without contraception
  • Patient under tutorship, curatorship or deprived of liberty

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Classical exercise training modality in concentric mode (CON)
Description: Control group, usual medical care according to the rehabilitation recommendations

ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.

The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.

Experimental: experimental, active group (ECC)
Patients perform a mixed program combining eccentric pedalling session with the usual sessions

ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.

The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
6 min. walk test (6-WT)
Time Frame: at day 1
6 min. walk test (6-WT)
at day 1
6 min. walk test (6-WT)
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
6 min. walk test (6-WT)
at the end of the rehabilitation program (at the end of the 5 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time up and go test (TUGT)
Time Frame: at day 1
Test that evaluates seated transfers, standing, walking and changes of direction.
at day 1
Time up and go test (TUGT)
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
Test that evaluates seated transfers, standing, walking and changes of direction.
at the end of the rehabilitation program (at the end of the 5 weeks)
Quadriceps isometric muscular strength
Time Frame: at day 1
The maximum muscle strength of the quadriceps (dominant limb) will be measured on a bench according to the instructions
at day 1
Quadriceps isometric muscular strength
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
The maximum muscle strength of the quadriceps (dominant limb) will be measured on a bench according to the instructions
at the end of the rehabilitation program (at the end of the 5 weeks)
Gait speed test
Time Frame: at day 1
Test that evaluate walking speed over 4 meters
at day 1
Gait speed test
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
Test that evaluate walking speed over 4 meters
at the end of the rehabilitation program (at the end of the 5 weeks)
Results of the incremental tests
Time Frame: at day 1
Peak VO2
at day 1
Results of the incremental tests
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
Peak VO2
at the end of the rehabilitation program (at the end of the 5 weeks)
Body composition measurements
Time Frame: at day 1
fat body mass
at day 1
Body composition measurements
Time Frame: at day 1
lean body mass
at day 1
Body composition measurements
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
fat body mass
at the end of the rehabilitation program (at the end of the 5 weeks)
Body composition measurements
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
lean body mass
at the end of the rehabilitation program (at the end of the 5 weeks)
Muscle Biopsie
Time Frame: at day 1
mitochondrial and histo-biochemical functionality from muscle biopsies
at day 1
Muscle Biopsie
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
mitochondrial and histo-biochemical functionality from muscle biopsies
at the end of the rehabilitation program (at the end of the 5 weeks)
Metabolomic analysis
Time Frame: at day 1
identification of specific blood and muscle biomarkers in response to retraining
at day 1
Metabolomic analysis
Time Frame: at the end of the rehabilitation program (at the end of the 5 weeks)
identification of specific blood and muscle biomarkers in response to retraining
at the end of the rehabilitation program (at the end of the 5 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ruddy RICHARD, University Hospital, Clermont-Ferrand

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 9, 2018

Primary Completion (Actual)

May 26, 2022

Study Completion (Actual)

May 26, 2022

Study Registration Dates

First Submitted

October 8, 2018

First Submitted That Met QC Criteria

October 22, 2018

First Posted (Actual)

October 23, 2018

Study Record Updates

Last Update Posted (Actual)

June 12, 2023

Last Update Submitted That Met QC Criteria

June 9, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHU-411
  • 2017-A00969-44 (Other Identifier: 2017-A00969-44)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rehabilitation Program

Clinical Trials on Eccentric rehabilitation sessions

3
Subscribe